Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022）

NCT05464433 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05464433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05464433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022）
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 23, 2022
Completion date
November 30, 2025
Enrollment
46 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal natural killer t cell lymphoma